Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–905.

Article  PubMed  CAS  Google Scholar 

Kudo M. Changing the treatment paradigm for hepatocellular carcinoma using atezolizumab plus bevacizumab combination therapy. Cancers (Basel). 2021;13(21):5475.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Cheng AL, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76(4):862–73.

Article  PubMed  CAS  Google Scholar 

Zanuso V, Pirozzi A, Balsano R, et al. Safety and efficacy of atezolizumab and bevacizumab combination as a first line treatment of advanced hepatocellular carcinoma. J Hepatocell Carcinoma. 2023;10:1689–708.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Lorenza R, Stephen LC, Bruno S, et al. Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC. J Hepatol. 2025;11:S0168-8278.

Google Scholar 

Xie F, Liu Z, Yang F, et al. Efficacy of immune checkpoint inhibitors plus molecular targeted agents in hepatocellular carcinoma. Front Immunol. 2022;13:105293.

Article  Google Scholar 

Kosaka Y, Kimura T, Kawaoka T, et al. Hepatic arterial infusion chemotherapy combined with radiation therapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk or bilobar of the portal vein. Liver Cancer. 2021;10:151–60.

Article  PubMed  PubMed Central  Google Scholar 

Fujino H, Kimura T, Aikata H, et al. Role of 3-D conformal radiotherapy for major portal vein tumor thrombosis combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. Hepatol Res. 2015;45:607–17.

Article  PubMed  CAS  Google Scholar 

Kudo M, Ueshima K, Yokosuka O, et al. Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial. Lancet Gastroenterology & Hepatology. 2018;3(6):424–32.

Article  Google Scholar 

Kodama K, Kawaoka T, Aikata H, et al. Comparison of outcome of hepatic arterial infusion chemotherapy combined with radiotherapy and sorafenib for advanced hepatocellular carcinoma patients with major portal vein tumor thrombosis. Oncology. 2018;94(4):215–22.

Article  PubMed  CAS  Google Scholar 

Xinyi Y, Xizhu F, Fangfang L, et al. Targeting TIME in advanced hepatocellular carcinoma: mechanisms of drug resistance and treatment strategies. Crit Rev Oncol Hematol. 2025;211:104735.

Article  Google Scholar 

Chen Y, Haoyue H, Yuan X, et al. Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma. Front Immunol. 2022;10(13):896752.

Article  Google Scholar 

Jiang J, Zhang H, Yanjiao O, et al. The immune-reinforcements of Lenvatinib plus anti-PD-1 and their rationale to unite with TACE for unresectable hepatocellular carcinoma treatment. Immunol Lett. 2025;275:107003.

Article  PubMed  CAS  Google Scholar 

Ikeda M, Yamashita T, Ogasawara S, et al. Multicenter Phase II Trial of Lenvatinib plus Hepatic Intra-Arterial Infusion Chemotherapy with Cisplatin for Advanced Hepatocellular Carcinoma: LEOPARD. Liver Cancer. 2023;13(2):193–202.

Article  PubMed  PubMed Central  Google Scholar 

Terashima T, Yamamoto M, Toyama T, et al. The efficacy and safety of adding hepatic arterial infusion chemotherapy using cisplatin to lenvatinib for advanced hepatocellular carcinoma. Hepatol Res. 2025;55(7):1026–37.

Article  PubMed  CAS  Google Scholar 

Thomas Yau, Peter R Galle, Thomas Decaens, et al. Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial. Lancet. 2025:S0140–6736(25)00403–9.

Shirali AC, Pedrazzoli P, Janus N, et al. Management of chemotherapy including cisplatin in patients with end-stage renal disease on hemodialysis. Nephrol Dial Transplant. 2017;32(5):800–7.

Google Scholar 

Liu Z, Lin Y, et al. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma. J Exp Clin Cancer Res. 2019;38:447.

Article  PubMed  PubMed Central  Google Scholar 

Zheng J, Huang A. Hepatocellular carcinoma: signaling pathways and systemic therapy progress. Signal Transduct Target Ther. 2025;10:75.

Google Scholar 

Dong H, Xie F, et al. Combination of immunotherapy and targeted therapy in hepatocellular carcinoma. Curr Treat Options Oncol. 2024;25:12.

Article  Google Scholar 

Grover SP, Hisada YM, Kasthuri RS, et al. Cancer Therapy-Associated Thrombosis. Arterioscler Thromb Vasc Biol. 2021;41(4):1291–305.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Rhian M Touyz, Sandra MS Herrmann, Joerg Herrmann, et al. Vascular toxicities with VEGF inhibitor therapies–focus on hypertension and arterial thrombotic events. J Am Soc Hypertension, 2018;12(6):409–425.